evipedia.ai
← Back

GLP-1 Receptor Agonists for Health & Longevity

Created on 10/28/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

GLP-1 receptor agonists, such as semaglutide and tirzepatide, are prescription medications copying a gut hormone to reduce appetite and lower blood sugar. In people with obesity, type 2 diabetes, or heart or kidney disease, trials show substantial weight loss and fewer heart attacks, strokes and deaths. Digestive side effects are common, some lost weight is muscle, and gains fade after stopping. Benefits and long-term safety in healthy adults are untested. (Full Review)

Protocol

Semaglutide injection (label regimen)
0.25 mg → 2.4 mg weekly
0.5, 1.0, 1.7 and 2.4 mg at 4-week steps, with a 7.2 mg high-dose presentation
Tirzepatide (Zepbound)
2.5 mg → 5, 10 or 15 mg weekly
Increased by 2.5 mg every 4 weeks or more
Longevity-practitioner approach
Lowest effective dose
Combined with high protein intake and resistance training to preserve lean mass; no trial has tested this approach
Time to effect
Weight loss
1–3 months
Maximum effect at 12–18 months
Cardiovascular event reductions
1–3 years
Seen in outcome trials
Appetite reduction
Within days
Appetite and food reward return within weeks of stopping

Benefits

Contraindications
  • Personal or family history of medullary thyroid carcinoma or MEN 2 (absolute contraindication)
  • Known serious hypersensitivity to the drug or its excipients (absolute contraindication)
  • Pregnancy, and planned pregnancy within 2 months for semaglutide
  • Breastfeeding while taking oral Wegovy tablets
  • Severe gastroparesis (not recommended)
  • Confirmed NAION during treatment (treatment is stopped)
  • Underweight (BMI below 18.5 kg/m²) or active eating disorders (inferred; no human data)
    •
Key Interactions
  • Insulin and insulin secretagogues (glimepiride): increased hypoglycemia, including severe events
  • Oral contraceptives with tirzepatide (ethinyl estradiol combinations): reduced contraceptive exposure and possible failure (for 4 weeks after starting and after each dose increase)
  • Levothyroxine with oral semaglutide: total thyroxine exposure rose, risking overtreatment
  • Narrow-therapeutic-index oral drugs (e.g., warfarin): absorption may be altered
  • Deep sedation or general anesthesia for procedures: retained gastric content raises the risk of pulmonary aspiration
  • CYP3A4 inhibitors and inducers with orforglipron (clarithromycin; carbamazepine): raise or lower orforglipron exposure (capped at 9 mg with strong inhibitors; avoided with strong inducers and ritonavir-type inhibitors)
  • Simvastatin with orforglipron: doubles exposure to active simvastatin acid (simvastatin capped at 20 mg daily)
  • Oral iron supplements: reduced intestinal iron absorption with semaglutide, risking iron deficiency
  • Other GLP-1 receptor agonists or semaglutide-containing products (liraglutide): duplicated effect and additive adverse events; co-administration avoided
    •
Theoretical (inferred from mechanism)
  • Glucose-lowering supplements (berberine): additive glucose lowering
  • Fiber and satiety supplements (psyllium): additive slowing of gastric emptying and fullness
  • Over-the-counter NSAIDs (ibuprofen) during vomiting or diarrhea: additive kidney stress
  • Over-the-counter laxatives and antidiarrheals (loperamide): may mask or worsen drug-related bowel symptoms
  • Alcohol: additive gastrointestinal irritation and, with sulfonylureas or insulin, delayed hypoglycemia
    •

Risk & Side Effects

  • High: Gastrointestinal adverse events; weight regain and metabolic rebound after stopping; gallbladder and biliary disease; low blood pressure and fainting
    •
  • Medium: Lean mass loss; severe gastrointestinal complications; optic nerve stroke; resting heart rate increase; hypoglycemia with insulin or sulfonylureas; fatigue, headache, dizziness, hair loss and altered taste; dysesthesia at high semaglutide doses; injection-site reactions; severe allergic reactions; kidney stones; appendicitis
    •
  • Low: Acute pancreatitis; thyroid cancer; diabetic retinopathy worsening; neovascular macular degeneration; acute kidney injury from dehydration; pulmonary aspiration during anesthesia; suicidal ideation and psychiatric events; bone fractures
    •
  • Speculative: Unknown long-term effects in lean, healthy users
    •

Monitoring

Marker Target Why
HbA1c 4.0–5.6% Glucose control
Fasting glucose 70–99 mg/dL Hypoglycemia safety check
LDL cholesterol and triglycerides No established target; track change from own baseline Lipid change
Creatinine / eGFR Creatinine about 0.6–1.3 mg/dL Dehydration-related kidney injury
ALT About 7–56 U/L Liver fat
Lipase About 13–60 U/L Pancreatitis check
hs-CRP No established target; track change from own baseline Inflammation
Ferritin Men about 31–409 ng/mL; women aged 18–50 about 6–175 ng/mL Iron deficiency
Lean mass (DXA) No established target; track change from own baseline Lean-mass loss
Resting heart rate 60–100 beats per minute Heart-rate increase
Body weight Not specified in the ER Baseline reference point
Waist circumference Not specified in the ER Baseline reference point
Blood pressure Not specified in the ER Baseline reference point
Grip strength Not specified in the ER Paired with lean mass
Complete blood count Not specified in the ER Paired with ferritin

Cadence: Baseline before starting; every 4 weeks during dose escalation for weight, heart rate, symptoms and hydration; labs at 3 months, then every 6–12 months; DXA every 6–12 months during active weight loss

Qualitative Assessment

  • Appetite control and fewer intrusive thoughts about food
  • Energy levels and exercise performance, including strength trends
  • Gastrointestinal tolerance (nausea, bowel habits, reflux)
  • Sleep quality and daytime alertness
  • Mood, motivation and alcohol craving
  • Vision changes, especially sudden loss in one eye
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.